ANF Stock Soars After Q3 Earnings Beat and Raised Guidance Skip to Main Content

Abercrombie & Fitch Stock Rockets After Q3 Beat and Strong FY2025 Guidance

|
Share on social media

Abercrombie & Fitch (ANF) stock rocketed 37% higher following a strong Q3 earnings report that beat both revenue and EPS estimates while raising full-year guidance. The apparel retailer reported Q3 adjusted EPS of $2.36, beating the $2.16 consensus by nearly 10%, with revenue of $1.29 billion up 6.7% year-over-year. Management raised FY2025 EPS guidance to $10.20-$10.50 from $10.00-$10.50, signaling confidence despite a softening consumer backdrop. Multiple analysts responded positively, with UBS raising its price target to $130 and Morgan Stanley lifting its target from $78 to $95.

anf stock

Key Drivers of the ANF Stock Move

  • Earnings Beat and Raised Guidance: Q3 adjusted EPS of $2.36 exceeded expectations by 9.4%, while the company lifted FY2025 net sales growth guidance to 6%-7% from 5%-7%. Q4 EPS guidance of $3.40-$3.70 also came in line with estimates, demonstrating operational discipline.
  • Bull Case: The company has proven it can navigate a challenging retail environment while maintaining pricing power and brand momentum. Analyst upgrades following the report suggest institutional confidence in the turnaround story continuing. November historically delivers strong returns for ANF, with 80% positive periods and a median gain of 19.4% based on five-year data.
  • Bear Case: Despite the beat, EPS declined 5.6% year-over-year, marking the second consecutive quarter of negative earnings growth. The stock’s relative performance versus sector peers had deteriorated dramatically from a 72 percentile in early September to just 19 by late November before this earnings spike, suggesting vulnerability to broader retail weakness.

The primary risk remains execution in a softening consumer discretionary environment. While the stock has rebounded sharply from recent lows, it faces challenging comparisons and potential margin pressure. Investors should watch for sustained relative strength versus the retail sector and confirmation that the guidance raise was conservative rather than optimistic.

anf stock chart

ANF Smart Money Activity

Insider activity has been minimal, with only routine stock appreciation rights dispositions. Director Kenneth Robinson sold $131,700 worth of shares in early September, while two directors received awards in early November. No congressional trades were reported during the period.

ANF Smart Money Activity

ANF Unusual Options

Options activity exploded around earnings, with heavy call buying dominating on November 25th as the stock surged. Notable flows included $700K in January 2026 $60 calls traded near the bid (potentially closing positions), $500K in January 2026 $60 calls, and aggressive sweeps in near-term $85-$91 strikes as the stock climbed through resistance. Before earnings on November 24th, protective put buying in December $65-$70 strikes indicated hedging, with $350K in December $65 puts purchased. Post-earnings flows skewed bullish, with leap calls in 2027 $100-$120 strikes attracting interest, suggesting longer-term conviction.

and unusual options

ANF Seasonality

Examining 11 years of historical data from 2015 forward, ANF exhibits pronounced seasonal tendencies. November stands as the dominant month with a 73% win rate and an extraordinary 17.2% average gain—nearly triple the next strongest period. January and September provide secondary strength, posting 55% and 64% win rates, respectively, with January averaging 4.7% gains and September 2.3%.

ANF Seasonality

ANF Relative Performance

ANF’s relative performance against its sector peers had deteriorated sharply through October and early November, falling from the 72nd percentile in early September to just the 13th percentile by mid-October. The stock underperformed 87% of its consumer discretionary peers during this period. However, the earnings-driven surge on November 25th catapulted relative performance back to the 53rd percentile, reclaiming the median position among sector names. This dramatic reversal suggests the market had become overly pessimistic heading into the print.

ANF Analyst Focus

Analyst sentiment improved markedly post-earnings. UBS maintained its Buy rating while raising its price target from $125 to $130 on November 26th. Morgan Stanley lifted its target from $78 to $95 while maintaining Equal-Weight, and JP Morgan raised its Neutral-rated target from $92 to $109. Telsey Advisory Group held its Outperform rating with a $125 target. Prior to earnings, several firms had reduced targets through October and November, with Jefferies cutting from $130 to $100 and Citigroup slashing from $105 to $79, reflecting concerns about sector headwinds. The median price target now sits near $109, implying modest upside from current levels near $95.

ANF stock analyst ratings

Stay up-to-date: Subscribe to posts like this!

Receive automated updates from the Posts category
This site is protected by reCAPTCHA and the Google Privacy Policy and Google Terms of Service apply. Don't worry, we hate spam, too! See TrendSpider Privacy Policy for details.

Latest posts

|

Jensen Huang Resigns as NVIDIA CEO: What it Means for NVDA Stock

After 33 years at the helm of the company he co-founded, Jensen Huang resigned as President, CEO, and board member of NVDA effective immediately on November 12, 2026. The departure was triggered by a deepening scandal involving alleged ties to a suspected Chinese intelligence asset, a second workplace affair, and a cascade of regulatory and […]
|

CoreWeave Stock Q3 Earnings: $3.7B Revenue Beat & 2026 Guide Raise

CoreWeave (CRWV) stock delivered a commanding Q3 2026 earnings beat on November 10, posting revenue of $3.7 billion against a consensus estimate of $3.5 billion and an adjusted EPS loss of $0.95 versus the expected $1.53 — a 38% EPS beat. The company simultaneously raised its full-year 2026 revenue guidance to $13.0–$13.3 billion, sparking an […]
|

Hims & Hers Stock Slides as Q3 EPS Miss & Weak Guide Shadow 49% Sales

Hims & Hers Health (HIMS) stock delivered another quarter of robust top-line expansion in Q3 2026, with revenue surging 48.7% year-over-year to $890.4M. However, an adjusted EPS miss and a materially below-consensus Q4 outlook sent shares sharply lower after the report, reflecting growing investor concern about profitability and the post-GLP-1 compounding transition. Key Takeaways: Beat […]
|

Rocket Lab Corporation Stock Drops as Q3 EPS Miss & Neutron Slip Outshine 73% Sales

Rocket Lab Corporation (RKLB) stock reported its strongest quarter on record in Q3 2026, with revenue surging 72.7% year-over-year to $267.8M, beating the $257.0M consensus by 4.2%. However, an adjusted EPS miss of -$0.08 versus the -$0.07 estimate, compounding concerns around the Neutron rocket’s delayed debut, sent shares tumbling more than 8% in after-hours trading […]